ClinicalTrials.Veeva

Find clinical trials for Lung Cancer in Montréal, QC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Cancer
Carcinoma
Small Cell Lung Carcinoma
Squamous Cell Carcinoma of Head and Neck
Colorectal Cancer
Triple Negative Breast Cancer

Lung Cancer trials near Montréal, QC, CAN:

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)

and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, metastatic non-small cell lung cancer...

Active, not recruiting
Squamous Non Small Cell Lung Cancer
Nonsquamous Non Small Cell Lung Cancer
Drug: Zimberelimab
Drug: Domvanalimab

Phase 2

Arcus Biosciences
Arcus Biosciences

Montréal, Canada and 64 other locations

a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: LN-145

Phase 2

Iovance Biotherapeutics

Montréal, Canada and 43 other locations

with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....

Active, not recruiting
Non-small Cell Lung Cancer
Drug: DS-1062a
Drug: Docetaxel

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Montréal, Quebec, Canada and 205 other locations

to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previous...

Enrolling
Non-Small Cell Lung Cancer
Drug: docetaxel
Drug: JDQ443

Phase 3

Novartis
Novartis

Montreal, Quebec, Canada and 155 other locations

, early-stage non-small cell lung cancer....

Enrolling
Non-small Cell Lung Cancer
Drug: Cisplatin
Drug: Oleclumab

Phase 2

AstraZeneca
AstraZeneca

Montreal, Quebec, Canada and 94 other locations

This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as...

Active, not recruiting
Small Cell Lung Cancer
Drug: Durvalumab
Other: Placebo

Phase 3

AstraZeneca
AstraZeneca

Montreal, Quebec, Canada and 181 other locations

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemothe...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Paclitaxel
Procedure: Surgery

Phase 3

AstraZeneca
AstraZeneca

Montreal, Quebec, Canada and 230 other locations

combination with pembrolizumab in participants with non-small cell lung cancer (NSCLC).Each treatment cycle lasts 21 days. Particip...

Enrolling
Lung Cancer Metastatic
Lung Cancer Stage IV
Drug: SLC-391
Biological: pembrolizumab

Phase 1, Phase 2

SignalChem Lifesciences

Montréal, Quebec, Canada and 12 other locations

of lurbinectedin with irinotecan (Group B) versus Investigator's Choice (topotecan or irinotecan) as control arm (Group C), in Small-cell Lung...

Enrolling
Relapsed Small Cell Lung Cancer
Drug: Irinotecan
Drug: Lurbinectedin

Phase 3

Pharma Mar

Montréal, Canada and 213 other locations

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that overexpress c-Met (c-Met+) best...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Telisotuzumab vedotin

Phase 2

AbbVie
AbbVie

Greenfield Park, Quebec, Canada and 252 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems